arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoriska syncytialvirusinfektioner - vacciner - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.
docenz injektionsvätska, suspension, förfylld spruta
mimer medical - influensavirus a/new caledonia/20/99 (h1n1)-liknande stam (a/new caledonia/20/99 (ivr-116)), ytantigen, inaktiverat; influensavirus b/hong kong/330/2001-liknande stam (b/shangdong/7/79), spjälkat virus, inaktiverat; influesavirus a/moscow/10/99(h3n2)-liknande stam (a/panama/2007/99 (resvir-17)), ytantigen, inaktiverat - injektionsvätska, suspension, förfylld spruta - influensavirus b/hong kong/330/2001-liknande stam (b/shangdong/7/79), spjälkat virus, inaktiverat 15 mikrog aktiv substans; influesavirus a/moscow/10/99(h3n2)-liknande stam (a/panama/2007/99 (resvir-17)), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/new caledonia/20/99 (h1n1)-liknande stam (a/new caledonia/20/99 (ivr-116)), ytantigen, inaktiverat 15 mikrog aktiv substans - spjälkat virus eller ytantigen
lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
baymite vet 500 mg/ml koncentrat till spray, emulsion
bayer animal health gmbh - foxim - koncentrat till spray, emulsion - 500 mg/ml - foxim 500 mg aktiv substans - foxim - fjäderfä
enalapril comp ratiopharm 20 mg/12,5 mg tablett
ratiopharm gmbh - enalaprilmaleat; hydroklortiazid - tablett - 20 mg/12,5 mg - hydroklortiazid 12,5 mg aktiv substans; enalaprilmaleat 20 mg aktiv substans; laktosmonohydrat hjälpämne - enalapril och diuretika
monofer 100 mg/ml injektions-/infusionsvätska, lösning
paranova läkemedel ab - järn(iii)derisomaltos - injektions-/infusionsvätska, lösning - 100 mg/ml - järn(iii)derisomaltos 417 mg aktiv substans
lisiliv 10 mg tablett
antibiotice sa - lisinoprildihydrat - tablett - 10 mg - lisinoprildihydrat 10,89 mg aktiv substans; mannitol hjälpämne
lisiliv 20 mg tablett
antibiotice sa - lisinoprildihydrat - tablett - 20 mg - lisinoprildihydrat 21,78 mg aktiv substans; mannitol hjälpämne
methylphenidate stada 36 mg depottablett
stada arzneimittel ag - metylfenidathydroklorid - depottablett - 36 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 6,48 mg aktiv substans; metylfenidathydroklorid 29,52 mg aktiv substans
methylphenidate stada 18 mg depottablett
stada arzneimittel ag - metylfenidathydroklorid - depottablett - 18 mg - metylfenidathydroklorid 14,76 mg aktiv substans; metylfenidathydroklorid 3,24 mg aktiv substans; laktosmonohydrat hjälpämne